Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Quoin Pharmaceuticals Ltd - AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
QNRX
Nasdaq
8731
https://quoinpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Quoin Pharmaceuticals Ltd - AD
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript
- Mar 15th, 2024 2:52 pm
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
- Mar 13th, 2024 8:05 pm
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
- Mar 7th, 2024 9:05 pm
QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths
- Mar 5th, 2024 3:12 pm
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
- Mar 5th, 2024 1:00 pm
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
- Mar 4th, 2024 1:00 pm
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
- Feb 8th, 2024 1:00 pm
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
- Dec 13th, 2023 1:30 pm
QNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approval
- Nov 13th, 2023 2:00 pm
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 5:19 pm
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
- Nov 8th, 2023 10:46 pm
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
- Nov 3rd, 2023 12:41 pm
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
- Oct 24th, 2023 1:32 pm
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
- Oct 24th, 2023 12:28 pm
QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials
- Oct 2nd, 2023 4:25 pm
Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders
- Aug 9th, 2023 12:30 pm
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
- Aug 2nd, 2023 8:45 pm
Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET
- Jul 27th, 2023 12:00 pm
Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
- May 24th, 2023 12:15 pm
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
- May 8th, 2023 9:00 pm
Scroll